Pfizer's trouble-prone McPherson plant — now ramping up vaccine supplies — was cited for continuing violations in early 2020
A few days ago, as Pfizer CEO Albert Bourla committed to ramping up production of its Covid-19 vaccine, the pharma giant pointed to plans to add its manufacturing plant in McPherson, KS to the group of facilities churning out their mRNA vaccine developed by BioNTech.
But a quick check of Google would show anyone that the plant, obtained from Hospira in the 2015 buyout, has regularly been in hot water with the FDA over violations of federal regulatory standards. Most significantly, Pfizer earned a harsh warning letter from the FDA in 2017 that made it clear the FDA wasn’t happy with the remediation efforts being made at the plant in the 2 years since the acquisition.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 148,200+ biopharma pros reading Endpoints daily — and it's free.